论文部分内容阅读
目的探讨应用右旋糖酐氢氧化铁注射液(商品名为科莫非)治疗缺铁性贫血(IDA)的临床效果。方法在为我院近年来收治的120例缺铁性贫血患者进行治疗的过程中,按照随机对照的原则将其分为观察组和对照组,每组各60例患者。为对照组患者使用右旋糖酐铁进行肌注治疗,为观察组患者使用科莫非进行静点治疗。观察两组患者治疗前后Hb的上升幅度、时间和不良反应。结果治疗1周后,两组患者的Hb均有所上升,但治疗组患者Hb上升的幅度明显高于对照组患者。在(17.2±3.9)d为患者补足所需补铁总量时,观察组患者的Hb为(108.2±9.1)g/L,对照组患者的Hb为(75.8±8.8)g/L。对照组患者的Hb达到观察组患者水平所用的额外补铁时间为(38.1±13.2)d;在治疗过程中,观察组患者未出现明显的不良反应,而对照组患者大多出现了注射部位疼痛及色素沉着等不良反应。结论用科莫非治疗IDA安全有效,能迅速提高患者的Hb,并可避免进行输血治疗,并能为患者减轻经济负担。
Objective To investigate the clinical effect of iron dextran (IDA) treated with dextran iron hydroxide injection (trade name Comoprofill). Methods In our hospital for treatment of 120 patients with iron deficiency anemia in recent years, according to the principle of randomized control will be divided into observation group and control group, each group of 60 patients. Patients in the control group received intramuscular injection of iron dextran, and patients in the observation group were treated with comorino for intravenous injection. Observe Hb rise, time and adverse reactions before and after treatment in two groups of patients. Results After one week of treatment, the Hb in both groups increased, but the Hb level in the treatment group was significantly higher than that in the control group. Hb was (108.2 ± 9.1) g / L in the observation group and (75.8 ± 8.8) g / L in the control group at (17.2 ± 3.9) days when the patient needed to make up the required amount of iron supplementation. In the control group, the additional iron supplementation time for Hb to reach the observation group was (38.1 ± 13.2) days. No significant adverse reactions were observed in the observation group during the course of treatment, while most patients in the control group developed pain in the injection site and Pigmentation and other adverse reactions. Conclusions The safe and effective treatment of IDA with Comoprofen can rapidly increase Hb in patients, avoid transfusion therapy and reduce the financial burden on patients.